Table 3.
Baseline patient and lesion characteristics by type of immunotherapy.
| Patient characteristic | Anti-CTLA-4 (n=54) |
Anti-PD-1 (n=21) | p value |
|---|---|---|---|
| Mean age at first SRS (yrs) | 62.9 | 61.9 | 0.7579 |
| Sex | |||
| Male | 34 (63%) | 17 (81%) | 0.134 |
| Female | 20 (37%) | 4 (19%) | |
| Median KPS | 100 (50-100) | 90 (70-100) | 0.259 |
| Median melanoma-specific GPA | 3 (0-4) | 3 (1-4) | 0.331 |
| History of WBRT before SRS | 5 (9%) | 0 (0%) | 0.149 |
| Active systemic disease | 46 (85%) | 15 (71%) | 0.170 |
| Median time from initial melanoma diagnosis to development of BrMets (months) |
38.9 (0-318) | 27.8 (0-204) | 0.5225 |
| BRAF status* | |||
| Mutated | 15 (28) | 7 (33) | 0.399 |
| Wild-type | 17 (31) | 13 (62) | |
| Prior chemotherapy | 16 (30%) | 2 (10%) | 0.067 |
| BRAF inhibitor | 8 (15%) | 7 (33%) | 0.072 |
| Median number of BrMets treated per SRS session |
3 (1-20) | 2 (1-23) | 0.1472 |
| Lesion characteristic | n=438 | n=128 | |
| Median lesion volume (mm3) | 85.7 (4-27482) | 229.6 (4-10370) | <0.0001 |
| Median dose (Gy) | 20 (12-24) | 18 (12-22) | <0.0001 |
| Timing of SRS | |||
| Concurrent | 204 (47%) | 109 (85%) | <0.0001 |
| Non-concurrent | 234 (53%) | 19 (15%) |
*
not all patients were tested for BRAF status